Core Viewpoint - CMB.TECH reported a profit of USD 17.3 million for Q3 2025, a significant decrease from USD 98.1 million in Q3 2024, while EBITDA increased to USD 238.4 million from USD 177.1 million year-over-year, indicating a recovery in tanker and dry bulk markets after a soft summer [4][5][6]. Financial Highlights - Revenue for Q3 2025 was USD 454.2 million, compared to USD 221.8 million in Q3 2024, with year-to-date revenue reaching USD 1.08 billion, up from USD 714.2 million in the previous year [5][6]. - The company’s contract backlog stands at USD 2.95 billion, reflecting strong future revenue potential [6]. - An interim dividend of USD 0.05 per share is proposed, expected to be paid on or about January 15, 2026 [10]. Fleet Highlights - CMB.TECH took delivery of seven new vessels in Q3 2025, including Super-Eco Newcastlemax and VLCC Atrebates, while selling two older vessels [6][14][15]. - The average daily time charter equivalent (TCE) rates for various vessel types showed mixed results, with Newcastlemax at USD 29,423/day and VLCC at USD 30,486/day for Q3 2025 [11][39]. Corporate Highlights - Changes in the Supervisory Board included the resignation of Mr. Marc Saverys and Mrs. Julie De Nul, with Mr. Carl Steen and Mrs. Gudrun Janssens appointed as new members [12][13]. - The company continues to focus on rejuvenating and decarbonizing its fleet, with ongoing sales and acquisitions of vessels [5][6]. Market & Outlook - The dry bulk market is expected to benefit from increased iron ore imports to China, despite a decrease in domestic steel production, indicating a bullish outlook for seaborne trade [19][20]. - The tanker market is supported by rising global oil supply, with OPEC+ increasing production, which may lead to improved freight rates [26][29]. - The chemical tanker market remains stable, with expectations of modest recovery in volume growth in 2026 [36][37].

Core Viewpoint - Lassila & Tikanoja Plc is undergoing a demerger, creating a new independent company focused on circular economy, named New Lassila & Tikanoja, while the existing company will be renamed Luotea Plc, focusing on facility services [1][3]. Company Overview - The demerger plan was approved on 7 August 2025, with the new company expected to be listed on Nasdaq Helsinki Ltd [1][3]. - The Capital Markets Day is scheduled for 26 November 2025, focusing on the business prospects and strategies of both New Lassila & Tikanoja and Luotea [2][4]. Business Focus and Strategy - Luotea will concentrate on facility services, providing comprehensive solutions throughout the lifecycle of buildings, emphasizing energy efficiency and smart technologies [6][7]. - The target market size for Luotea is approximately EUR 12.2 billion, with an expected annual growth rate of about 4% [8]. Financial Performance - Preliminary unaudited financial information for Luotea shows net sales of EUR 347.4 million, with an adjusted EBITDA of EUR 20.0 million and an adjusted EBITDA margin of 5.8% for the period from 1 October 2024 to 30 September 2025 [15][16]. - The company aims for an average annual organic revenue growth of 4–5% and an adjusted EBITA margin exceeding 5% in the mid-term [17]. Customer Base and Market Position - Luotea has a diverse customer base of over 6,000 clients, with a low turnover rate, and has optimized its contract portfolio to increase high-profitability contracts [10][11]. - The company is positioned to leverage cross-selling opportunities and expand into new segments, particularly in the public sector [14].

Core Insights - Kuros Biosciences will present at the Piper Sandler 37th Annual Healthcare Conference, showcasing its innovative biologic technologies and commercial momentum [1][2] - The presentation will focus on clinical advancements in the MagnetOs portfolio, expansion into new indications, and the company's path to sustainable profitability [2] Company Overview - Kuros Biosciences is dedicated to discovering, developing, and delivering innovative biologic technologies, with operations in the United States, Switzerland, and the Netherlands [7] - The company's first commercial product, MagnetOs, is an advanced bone graft used globally across five continents [7] Product Details - MagnetOs has demonstrated a fusion rate of 79% in a Level I clinical study, nearly double that of autograft at 47% [5] - The product utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and is FDA cleared for use throughout the spine [5] Presentation Details - The presentation will be led by Chris Fair, CEO of Kuros Biosciences, on December 3, 2025, at The Lotte New York Palace in New York City [3] - A live webcast of the presentation will be available for 30 days post-event [3]

Core Insights - Valneva SE announced positive final immunogenicity and safety data from the Phase 2 study of its Lyme disease vaccine candidate, VLA15, confirming strong immune response and safety six months after a third booster dose [1][3][4] - VLA15 is the furthest advanced Lyme disease vaccine in clinical development, with pivotal Phase 3 trials ongoing and plans for regulatory submissions in 2026 [2][5] Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [9][11] - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [10] Vaccine Development - VLA15 is a multivalent protein subunit vaccine targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria causing Lyme disease, and covers the six most prevalent OspA serotypes in North America and Europe [5][8] - The Phase 2 study, VLA15-221, included a pediatric population and demonstrated that antibody levels remained well above baseline across all serotypes and age groups six months after the third booster dose [6][7] Clinical Study Results - The study confirmed the benefits of a three-dose vaccination schedule and a yearly booster, with geometric mean fold rises (GMFRs) in antibody levels ranging from 9.5-fold to 15.6-fold across all age groups [3][4] - No safety concerns were observed by the independent Data Monitoring Committee (DMC) in any vaccination or age group, indicating a favorable safety profile [4][6] Market Context - There are currently no approved human vaccines for Lyme disease, with approximately 476,000 diagnoses in the U.S. and 132,000 cases reported annually in Europe, highlighting a significant unmet medical need [2][8] - The increasing geographic spread of Lyme disease underscores the importance of developing effective vaccination strategies [3][8]

Core Viewpoint - The Conference of the International Trade and Investment Advisory Council for Shandong Province 2025 focused on enhancing Shandong's role as a hub for high-standard international cooperation through discussions on green, low-carbon, and high-quality development [4]. Group 1: Conference Overview - The conference was held on November 24, 2025, in Jinan, Shandong Province, and was organized by the China Council for the Promotion of International Trade (CCPIT) Shandong Sub-council [4]. - Over 50 international advisors and delegates from more than 10 countries participated, including representatives from the United States, Germany, Britain, Italy, Mexico, Malaysia, Singapore, and Kenya [4]. Group 2: Advisory Mechanism and Reports - Seven new advisors were appointed during the conference, expanding Shandong's international think tank [5]. - A total of 18 advisory reports were submitted, covering areas such as green and low-carbon initiatives, biopharmaceuticals, digital economy, and cross-border economic cooperation [7]. - The advisory mechanism has engaged prominent figures from the global business community since its launch in December 2021 [8]. Group 3: Policy Recommendations and Implementation - Advisors have submitted over 50 policy recommendations addressing Shandong's key development priorities, contributing to energy consumption reductions and the growth of green industries [10]. - The mechanism has facilitated trade and investment projects, with significant investments including 10 billion yuan from Singapore RGE Group for a Lyocell fiber production base and 3.5 billion yuan projected from ERGO International for insurance sector partnerships [11].

Core Insights - Faraday Future has signed a strategic cooperation with Ras Al Khaimah Innovation City to develop a new regional energy mobility ecosystem and plans to expand its operations facility in Ras Al Khaimah [1][2][3] Group 1: Strategic Developments - The collaboration with Ras Al Khaimah Innovation City marks a new phase in Faraday Future's Middle East strategy, focusing on creating an EAI intelligent mobility ecosystem [2] - The company operates a manufacturing and operations center in Ras Al Khaimah, covering 108,000 square feet, which supports production for both Faraday Future and FX vehicles [3] Group 2: Product Launch and Market Response - The FX Super One was officially launched in Dubai on October 28, 2025, priced at AED 309,000, and received over 200 B2B paid pre-orders within 48 hours [6] - The inaugural global delivery ceremony for the FX Super One is scheduled for November 27, where the first vehicle will be delivered to soccer star Andrés Iniesta [4] Group 3: Leadership Perspectives - Tin Mok, Head of FF UAE, highlighted the strategic positioning of Ras Al Khaimah Innovation City as an AI-driven free zone, which aligns with the innovative goals of Faraday Future and FX [5] - Paul Dawalibi, CEO of Ras Al Khaimah Innovation City, expressed strong expectations for the partnership, emphasizing the importance of FF and FX as innovation partners [5]

Core Insights - TTEC Holdings, Inc. announced a significant expansion of its operations in Egypt, following the 2025 Global Offshoring Summit in Cairo [1][3] - The company plans to increase its workforce in Cairo by 3,500 employees by 2029 to meet rising global client demand [3][6] - TTEC's Cairo facility will serve as a strategic global hub for delivering integrated omnichannel customer experience (CX) support and piloting next-generation technologies [5][6] Company Expansion - TTEC first entered the Egyptian market in 2023 and expanded in early 2025 with a new facility in Maadi Technology Park, which currently employs over 500 staff [4][5] - The facility supports 11 languages, including Arabic, English, French, and Spanish, and will continue to grow as client needs increase [4][5] Strategic Importance - Egypt is positioned as a key part of TTEC's global delivery network, leveraging the country's multilingual talent and government support [5][7] - The expansion is expected to create thousands of jobs across various functions, including frontline support, operations, and technology [6][7] Technological Advancements - TTEC's Cairo operations will enhance its ability to provide omnichannel support, including voice, chat, and analytics, while also serving as an innovation hub for AI-enabled solutions [5][6] - The company emphasizes extensive training in AI tools, cloud systems, and cybersecurity for its workforce [6]

Core Points - Faircourt Asset Management Inc. announced a monthly distribution for the Faircourt Gold Income Corp. fund, with a distribution amount of $0.024 per share [1][2] - The ex-dividend date is set for November 28, 2025, with the record date also on November 28, 2025, and the payable date on December 12, 2025 [2] Company Information - Faircourt Asset Management Inc. serves as the Investment Advisor for Faircourt Gold Income Corp. [2] - The Faircourt Fund is traded on the CBOE under the symbol FGX [2] Additional Information - Investors should be aware of ongoing fees and expenses associated with owning units of an investment fund, and detailed information can be found in public filings [3]

Core Insights - Fountain Asset Corp. reported financial results for Q3 and the nine months ended September 30, 2025, highlighting significant gains and a strong financial position [1][6]. Q3 2025 Highlights - The company realized $1.48 million in gains from the sale of portfolio investments, benefiting from increased trading prices in the technology and mining sectors [4]. - Net assets were valued at $8.56 million or $0.13 per share, an increase from $5.51 million or $0.09 per share at the end of 2024, representing a 44% increase year to date on a per share basis [5][8]. - The net comprehensive loss was reduced to $0.03 million compared to a loss of $0.71 million in Q3 2024 [8]. - Total gains from investment activity amounted to $0.42 million, contrasting with losses of $0.43 million in Q3 2024 [8]. - Operating expenses were maintained at a low level of $0.14 million, down from $0.26 million in Q3 2024 [8]. Nine Months Ended September 30, 2025 Highlights - The company reported a net comprehensive income of $3.03 million, a significant turnaround from a net comprehensive loss of $1.65 million for the same period in 2024 [8]. - Total income from investment activity reached $4.07 million, compared to a total loss of $0.98 million for the nine months ended September 30, 2024 [8]. - Net realized gains on the sale of portfolio investments were $3.24 million, compared to net realized losses of $0.08 million in the prior year [8]. - Net unrealized gains on portfolio investments were $0.74 million, contrasting with net unrealized losses of $0.90 million for the same period in 2024 [8]. - Total expenses for the nine months were $1.02 million, up from $0.67 million in the previous year [8]. Company Overview - Fountain Asset Corp. operates as a merchant bank, providing equity financing, bridge loan services, and strategic financial consulting across various industries, including marijuana, oil & gas, mining, real estate, manufacturing, retail, financial services, and biotechnology [9].

Core Viewpoint - SC II Acquisition Corp. has announced the pricing of its initial public offering (IPO) of 15,000,000 units at a price of $10.00 per unit, with trading set to begin on November 26, 2025 [1] Company Overview - The Company is a blank check company formed to pursue a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses across any industry or geographical location [2] - The Company's sponsor is managed by Nukkleus Defense Technologies, Inc., a wholly-owned subsidiary of Nukkleus Inc, with Menny Shalom serving as the Chief Executive Officer and director [2] Offering Details - The IPO consists of 15,000,000 units, each comprising one Class A ordinary share and one right to receive one fifth (1/5) of a Class A ordinary share upon the completion of the initial business combination [1] - The offering is expected to close on November 28, 2025, subject to customary closing conditions [1] - D. Boral Capital is the sole book-running manager for the offering, with legal counsel provided by Ellenoff Grossman & Schole LLP and Appleby (Cayman) Ltd. [3] Additional Information - The Company has granted underwriters a 45-day option to purchase up to an additional 2,250,000 units at the IPO price to cover over-allotments [3] - A registration statement for the units and underlying securities became effective on November 25, 2025 [4]